PUBLIC COMPANY
save$BMYBRISTOL MYERS SQUIBB CO
$BMY63.83-1.27%Princeton, NJ, USupdated 1d ago
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multip read more
…
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval166 co-mentions · 83 sources
- drugOPDIVO166 co-mentions · 83 sources
- drugOPDIVO QVANTIG166 co-mentions · 83 sources
- drugnivolumab166 co-mentions · 83 sources
- company$CELG-RIBRISTOL MYERS SQUIBB CO84 co-mentions · 84 sources
- tagDrug Shortage1 co-mentions · 1 sources
- drugazacitidine1 co-mentions · 1 sources
- drugOnureg1 co-mentions · 1 sources
pipeline
3
marketed
0
phase 3
0
catalysts ytd
6
approvals ytd
2
recalls ytd
0
Pipeline(3)
pipeline depth3 products
3Unknown
drug
INREBIC
1 INDICATIONS AND USAGE INREBIC ® is indicated for the tr…
Tyrosine-protein kinase JAK2Receptor-type tyrosine-protein kinase FLT3
drugOPDIVO
1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination o…
Programmed cell death protein 1
drugOPDIVO QVANTIG
1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination o…
Programmed cell death protein 1
Upcoming
Recent(90d)
earnings (1)
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Apr 1, 26tax coverShanahan Karin · EVP, Chief Supply Chain & Ops1,692 sh
- Apr 1, 26option exerciseShanahan Karin · EVP, Chief Supply Chain & Ops3,307 sh
- Apr 1, 26option exerciseShanahan Karin · EVP, Chief Supply Chain & Ops3,307 sh
- Mar 31, 26grantSamuels Theodore R. II · director845 sh
- Mar 31, 26grantRice Derica W · director639 sh
- Mar 31, 26grantMcMullen Michael R. · director577 sh
🐶 Hiring Signal
next earnings Oct 29, 2026
Where BRISTOL MYERS SQUIBB CO is staffing up — a leading indicator of pipeline and commercial priorities.
News
- Cytokinetics brings patent suit against Bristol Myers, escalating rivalryCytokinetics and Bristol Myers Squibb are fierce market rivals. Now they’re rivals in court. Cytokinetics filed a lawsuit against Bristol Myers on Wednesday, seeking to invalidate a recently grante…endpoints · 1d ago
- Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from CelgeneThe clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.biopharma_dive · 1d ago
- STAT+: PBMs agree to display TrumpRx drug pricesBristol's Zenbexus wins accelerated approval, Novartis wins UK patent fight over Entresto, and more biotech news from The Readoutstat · 1d ago
- STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and moreThe FDA approved a Bristol oral treatment for advanced multiple myeloma, marking the debut of a new class of medicine for the blood cancerstat · 1d ago
- Capricor shares spike on CEO comments; Cytokinetics sues Bristol MyersThe FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.biopharma_dive · 1d ago
- STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug classThe FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.stat · 1d ago
- BMS welcomes new multiple myeloma drug as generics batter current portfolioThe FDA approves Zenbexus just as copycat competitors depress sales of Bristol Myers Squibb’s multiple myeloma drugs Pomalyst and Revlimid, which crashed 71% and 49% year-on-year, respectively, in…biospace · 1d ago
- MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighterDespite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs.fiercebiotech · 1d ago
- FDA approves Bristol Myers' multiple myeloma successorThe FDA has granted accelerated approval for a Bristol Myers Squibb pill called iberdomide for patients with multiple myeloma that’s returned or stopped responding to treatment. Iberdomide is marke…endpoints · 1d ago
- MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troublesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 2d ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that